Entering text into the input field will update the search result below

ZIOPHARM Oncology, Inc. (ZIOP) CEO Laurence Cooper on Q1 2020 Results - Earnings Call Transcript

May 07, 2020 11:06 PM ETAlaunos Therapeutics, Inc. (TCRT)
SA Transcripts profile picture
SA Transcripts

ZIOPHARM Oncology, Inc. (ZIOP) Q1 2020 Earnings Conference Call May 7, 2020 4:30 PM ET

Company Participants

Chris Taylor - Vice President, Investor Relations and Corporate Communications

Laurence Cooper - Chief Executive Officer

Satyavrat Shukla - Chief Financial Officer

David Mauney - President

Conference Call Participants

Alethia Young - Cantor Fitzgerald

David Novak - Raymond James

Ramakanth Swayampakula - H.C. Wainwright & Co., LLC

Thomas Flaten - Lake Street Capital Markets, LLC

Yale Jen - Laidlaw & Company


Greetings and welcome to the Ziopharm Oncology First Quarter 2020 Earnings Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being recorded.

It is now my pleasure to introduce your host, Chris Taylor, Investor Relations at Ziopharm. Thank you, sir. You may begin.

Chris Taylor

Thank you, operator. Good afternoon and welcome to the Ziopharm Oncology conference call and webcast to review results for the first quarter ended March 31, 2020. This afternoon we filed our 10-Q and issued our first quarter financial news release, both of which are available in the Investors section of our website, Ziopharm.com.

For informational purposes, we have also included in our webcast a set of PowerPoint slides to accompany today’s commentary. These slides can also be found on our website in the Investors section.

During this call, the company will make a number of forward-looking statements, including statements regarding the potential therapeutic candidates in our development pipeline, regulatory status, financial information and business trends. Forward-looking statements are subject to numerous risks and uncertainties as described in our 10-Q and within other filings that we may make with the SEC from time to time.

Participating on our call today for Ziopharm will be Dr. Laurence Cooper, Chief Executive Officer; Sath

Recommended For You


To report an error in this transcript, .Contact us to add your company to our coverage or use transcripts in your business. Learn more about Seeking Alpha transcripts here. Your feedback matters to us!
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.